Identification of a reactive metabolite of terbinafine: Insights into terbinafine-induced hepatotoxicity

Chemical Research in Toxicology

Volumn 14, Issue 2, 2001, Pages 175-181

  Iverson, S L ^a   Uetrecht, J P ^a,b  

^a UNIVERSITY OF TORONTO   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

7,7 DIMETHYLHEPT 2 EN 4 YNAL; ALDEHYDE DERIVATIVE; GLUTATHIONE; TERBINAFINE; UNCLASSIFIED DRUG;

ANIMAL CELL; ARTICLE; CONTROLLED STUDY; DRUG STRUCTURE; FEMALE; HUMAN; LIVER MICROSOME; LIVER TOXICITY; METABOLITE; NONHUMAN; PATHOGENESIS; PROTON NUCLEAR MAGNETIC RESONANCE; RAT;

ALDEHYDES; ALKANES; ANIMALS; ANTIFUNGAL AGENTS; CHOLESTASIS, INTRAHEPATIC; GLUTATHIONE; HEPATITIS, TOXIC; HUMANS; MAGNETIC RESONANCE SPECTROSCOPY; MICROSOMES, LIVER; NAPHTHALENES; OXIDATION-REDUCTION; RATS;

ANIMALIA;

EID: 0035107812     PISSN: 0893228X     EISSN: None     Source Type: Journal    
DOI: 10.1021/tx0002029     Document Type: Article

References (26)

1. Terbinafine: An update
2. Oral terbinafine: A new antifungal agent
3. Hepatitis associated with terbinafine therapy: Three case reports and a review of the literature
4. Hypersensitivity reaction to terbinafine
5. Adverse drug reactions of the new oral antifungal agents: Terbinafine, fluconazole, and itraconazole
6. Safety of oral terbinafine: Results of a postmarketing surveillance study in 25884 patients
7. Drug-induced cholestasis
8. Immunoallergic drug-induced hepatitis: Lessons from halothane
9. Bile duct obstruction is not a prerequisite for type I biliary epithelial cell hyperplasia
10. Clinical pharmacokinetics of terbinafine (Lamisil)
11. Pharmacokinetics of terbinafine and five known metabolites in children, after oral administration
12. Benzene and substituted benzenes
13. The carbon monoxide-binding pigment of liver microsomes. I. Evidence for its hemoprotein nature
14. Terbinafine-induced cholestatic liver disease
15. Terbinafine hepatotoxicity: Case report and review of the literature
16. Terbinafine associated hepatic injury
17. Terbinafine and fulminant hepatic failure
18. Cholestatic jaundice due to terbinafine
19. Terbinafine-induced prolonged cholestasis with reduction of interlobular bile ducts
20. Drug-related biliary damage: A peculiar condition involving a genetic predisposition?
21. The metabolism and toxicity of inhaled anaesthetic agents
22. Terbinafine. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in superficial mycoses
23. Absence of effect of terbinafine on the activity of CYP1A2, NAT-2 and xanthine oxidase
24. Multiple cytochrome P-450s involved in the metabolism of terbinafine suggest a limited potential for drug-drug interactions